EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2- a ] pyrimidines as topoisomerase II inhibitors

Mona S El-Zoghbi, Samiha A El-Sebaey, Hanan A Al-Ghulikah, Eman A Sobh

Journal of Enzyme Inhibition and Medicinal Chemistry · 2023

DOI: 10.1080/14756366.2023.2175209 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Enzyme Inhibition and Medicinal Chemistry, 2023. Verfasst von Mona S El-Zoghbi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Menoufia University, Menoufia, Egypt. Hauptthemen laut MEDLINE: Topoisomerase II Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Princess Nourah bint Abdulrahman University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

New thiazolopyrimidine derivatives 2, 3a-d, 4a-c, 5, 6a-c, and 7a,b were synthesised. All prepared compounds were evaluated by MTT cytotoxicity assay against three human tumour cell lines. Compounds 3c, 3d, 4c, 6a, 6b, and 7b exhibited potent to strong anticancer activity that was nearly comparable or superior to Doxorubicin. Compounds exhibiting significant cytotoxicity were further selected to study their inhibitory activity on the Topo II enzyme. Compound 4c was the most potent Topo II inhibitor with an IC50 value of 0.23 ± 0.01 µM, which was 1.4-fold and 3.6-fold higher than the IC50 values of Etoposide and Doxorubicin. Furthermore, compound 4c showed significant cell cycle disruption and apoptosis on A549 cells compared to control cells. Molecular docking of the most active compounds illustrated proper fitting to the Topo II active site, suggesting that our designed compounds are promising candidates for the development of effective anticancer agents acting through Topo II inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Topoisomerase II InhibitorsAntineoplastic AgentsHumansMolecular StructureStructure-Activity RelationshipMolecular Docking SimulationPyrimidinesDNA Topoisomerases, Type IIDoxorubicinCell ProliferationDrug Screening Assays, Antitumor

Stichwörter der Autor:innen

Topoisomerase II inhibitiorsanticancerapoptosiscell cyclethiazolopyrimidine

Substanzen

Topoisomerase II InhibitorsPyrimidinesAntineoplastic AgentsDNA Topoisomerases, Type IIDoxorubicin

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Menoufia University, Menoufia, Egypt.
  • Department of Pharmaceutical Organic Chemistry, Al-Azhar University, Nasr City, Cairo, Egypt.
  • Department of Chemistry, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

Förderung

  • Princess Nourah bint Abdulrahman University

Zitieren

APA

El-Zoghbi, M. S., El-Sebaey, S. A., Al-Ghulikah, H. A., & Sobh, E. A. (2023). Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2- a ] pyrimidines as topoisomerase II inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2023.2175209

Vancouver

El-Zoghbi MS, El-Sebaey SA, Al-Ghulikah HA, Sobh EA. Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2- a ] pyrimidines as topoisomerase II inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 2023. doi:10.1080/14756366.2023.2175209

BibTeX
@article{ElZoghbi2023,
  author = {El-Zoghbi, Mona S and El-Sebaey, Samiha A and Al-Ghulikah, Hanan A and Sobh, Eman A},
  title = {Design, synthesis, docking, and anticancer evaluations of new thiazolo[3,2- a ] pyrimidines as topoisomerase II inhibitors},
  journal = {Journal of Enzyme Inhibition and Medicinal Chemistry},
  year = {2023},
  doi = {10.1080/14756366.2023.2175209}
}
Kostenlos starten →